Protagonist Therapeutics, Inc. — Q1 2021 Form 10-Q Summary
Business context and reporting period
Protagonist Therapeutics is a clinical-stage biopharmaceutical company developing peptide-based medicines for hematology, inflammatory, and immunomodulatory diseases. The company has no approved products or product-sales revenue and operates as one reportable segment. This unaudited Form 10-Q covers the three months ended March 31, 2021, filed May 4, 2021.
Key programs include rusfertide (PTG-300) for polycythemia vera and hereditary hemochromatosis; PN-943 for ulcerative colitis; and PTG-200, PN-235, and PN-232 under the Janssen collaboration for inflammatory bowel disease.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| License and collaboration revenue | $6.2 million | $3.6 million | Up 70% |
| Research and development expense | $24.2 million | $18.8 million | Up 29% |
| General and administrative expense | $6.0 million | $4.6 million | Up 30% |
| Loss from operations | $24.0 million | $19.7 million | Loss increased 22% |
| Net loss | $24.0 million | $20.1 million | Loss increased 20% |
| Basic and diluted net loss per share | $0.54 loss | $0.72 loss | Improved per share due to higher share count |
| Net cash used in operating activities | $28.8 million | $15.8 million | Use increased $12.9 million |
Revenue was generated entirely from license and collaboration arrangements with related party Janssen. Revenue included approximately $5.6 million from the Janssen performance obligation and $0.6 million from additional services. The estimated transaction price for the initial Janssen performance obligation was $96.3 million at March 31, 2021, down from $98.6 million at December 31, 2020.
Research and development spending was led by rusfertide at $10.1 million, PN-943 at $7.7 million, PN-235 at $1.8 million, and preclinical and discovery research at $5.4 million. Stock-based compensation was $2.7 million, compared with $2.0 million in the prior-year quarter.
At March 31, 2021, cash and cash equivalents were $83.0 million, current marketable securities were $190.5 million, and noncurrent marketable securities were $6.3 million. Total cash, cash equivalents, and marketable securities were approximately $279.7 million. Total assets were $298.1 million and stockholders’ equity was $259.3 million.
The company had no outstanding term-loan balance and reported compliance with its debt covenants. A $50.0 million term-loan facility remained available subject to conditions, including clinical milestones; the filing states that $20.0 million remained available as of March 31, 2021. The company believes its existing liquidity and debt access will fund operations for at least the next 12 months, but expects to require substantial additional financing to advance clinical development and potential commercialization.
Material changes versus the prior comparable period
- Collaboration revenue increased $2.5 million, primarily from higher proportional-performance revenue and additional Janssen services.
- Research and development expense increased $5.5 million, principally because of higher rusfertide development and manufacturing costs, initiation of PN-235 clinical development, increased PN-943 costs, and greater preclinical research spending.
- PTG-200 development expense declined by $0.9 million because substantially all agreed services for its Phase 2 trial had been delivered by the company.
- General and administrative expense increased $1.4 million, including higher personnel, recruiting, market research, and legal costs related primarily to the Zealand arbitration.
- Operating cash use increased substantially, partly because $8.7 million of deferred Janssen revenue was recognized and the company recorded higher collaboration-partner receivables.
- Interest expense fell to zero following repayment of the company’s term debt in the second quarter of 2020. Interest income declined to $0.1 million from $0.5 million because of lower interest rates and changes in the investment portfolio.
- Weighted-average shares increased to 44.2 million from 27.7 million, reflecting prior equity offerings and resulting in a less negative loss per share despite a higher absolute net loss.
Guidance, outlook, commentary, risks, and unusual items
- The company completed enrollment in its ongoing Phase 2 rusfertide polycythemia vera study in April 2021 and expects to initiate a global Phase 3 study in early 2022, subject to development and regulatory progress.
- A further Phase 2 rusfertide study in up to 20 polycythemia vera patients was initiated during the first quarter. Preliminary hereditary hemochromatosis data were expected in the second half of 2021.
- PN-235 Phase 1 development was initiated in December 2020 and was expected to be completed in 2021. The company expected to initiate and complete a Phase 1 study for PN-232 in 2021.
- The company suspended guidance on the completion timeline for Janssen’s PTG-200 Phase 2 study because of COVID-19 uncertainty.
- COVID-19 had already caused clinical-trial delays and could further affect patient recruitment, clinical-site operations, manufacturing, supply chains, collaboration activities, and liquidity.
- The company expects continuing losses and increased research, development, commercialization, and administrative expenses. It has an accumulated deficit of $307.8 million and has never generated product revenue.
- The Janssen agreement provides potential future milestone payments, including a $7.5 million Phase 1 milestone and additional opt-in, development, regulatory, and sales milestones, but their timing and receipt are uncertain. Potential milestones of up to $1.0 billion and tiered royalties are contingent on future events.
- The company is engaged in arbitration with Zealand Pharma regarding whether rusfertide is subject to post-termination payment obligations. Management considered the probability of loss remote and recorded no accrual. If Zealand prevails, potential obligations could include up to $28.0 million of development and regulatory milestones, up to $100.0 million of sales milestones, and a low-single-digit royalty on worldwide net sales, in addition to certain costs.
- The company adopted the income-tax accounting simplification standard effective January 1, 2021 with no financial statement impact. No income tax expense was recorded in Q1 2021.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether rusfertide Phase 3 preparation and the planned early-2022 initiation remain on schedule, including regulatory alignment with the FDA and EMA.
- Clinical efficacy, safety, enrollment, and timing updates for rusfertide, PN-943, PN-235, PN-232, and the Janssen-sponsored PTG-200 program.
- The sustainability and accounting timing of Janssen collaboration revenue, including the reduction in the estimated transaction price to $96.3 million.
- Cash burn, remaining liquidity, the availability and conditions of the term-loan facility, and the timing and terms of future capital raises.
- The outcome and potential financial exposure of the Zealand arbitration.
- The extent of continuing COVID-19-related delays, manufacturing constraints, patient recruitment issues, or supply-chain disruptions.
- Potential dilution from future equity offerings, stock options, warrants, and other equity awards; 9.0 million potentially dilutive securities were excluded from Q1 diluted loss per share because they were anti-dilutive.